Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute)(Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute))

概要

基本信息

药物类型

间充质干细胞疗法

别名-

靶点-

作用方式-

作用机制-

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

勃起功能障碍局限性前列腺癌

非在研适应症-

原研机构

The Methodist Hospital Research Institute

在研机构

The Methodist Hospital Research Institute

非在研机构-

权益机构-

最高研发阶段临床1/2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute) 相关的临床试验

NCT07048314

/ Not yet recruiting临床1/2期IIT

A Randomized Clinical Trial to Assess Safety and Efficacy of Allogeneic Adipose-derived Mesenchymal Stem Cells in Promoting the Recovery of Erectile Function Post Radical Retropubic Prostatectomy of Localized Prostate Cancer

This is a phase 1/2 single center, pilot study to assess safety and efficacy of allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) and to evaluate the timing and combination effects of active treatment versus placebo in promoting the recovery of erectile function in patients undergoing radical retropubic prostatectomy (RALP) of localized prostate cancer.

开始日期2025-07-01

申办/合作机构

The Methodist Hospital Research Institute

100 项与 Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Allogeneic adipose-derived mesenchymal stem cells(The Methodist Hospital Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
勃起功能障碍	临床2期	美国	The Methodist Hospital Research Institute	2025-07-01
局限性前列腺癌	临床2期	美国	The Methodist Hospital Research Institute	2025-07-01